FOSTER ® - Beclomethasone + Formoterol
FOSTER ® is a drug based on Beclometasone dipropionate and Formoterol fumarate dihydrate.
THERAPEUTIC GROUP: Adrenergics for aerosols and other drugs for obstructive respiratory tract syndromes.
Indications FOSTER ® - Beclometasone + Formoterol
FOSTER ® is indicated in the treatment of asthma inadequately responsive to corticosteroid therapy alone or with short-acting B2 adrenergic agonists.
Mechanism of action FOSTER ® - Beclometasone + Formoterol
FOSTER ® is a medicinal product used in the treatment of asthma, consisting of a corticosteroid Beclometasone and a long-acting Beta 2 adrenergic agonist, Formoterol.
The aforementioned active ingredients, despite having decidedly different biological properties, contribute to the control of obstructive respiratory symptoms present in the course of asthmatic disease.
More precisely, Beclometasone, by actively controlling the secretion of inflammatory cytokines by the respiratory mucosa, reduces the degree of inflammation of the airways, leading to a rapid regression of the obstructive and congestive symptoms that characterize this pathology; Formoterol, on the other hand, by binding the Beta 2 adrenergic receptors, expressed by the bronchial smooth muscles, it limits the contractile degree, restoring the normal patency of the respiratory tract.
The different pharmacokinetic characteristics of the two active principles allow the establishment of biological activity in a very short time, a few minutes after administration, which lasts for several hours after inhalation.
Studies carried out and clinical efficacy
BECLOMETHASONE FORMOTEROL IN OXIDATIVE DAMAGE PROTECTION
Eur J Pharmacol. 2013 Oct 15; 718 (1-3): 418-27. doi: 10.1016 / j.ejphar.2013.08.001. Epub 2013 Aug 19.
Beclomethasone dipropionate and formoterol reduce oxidative / nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial epithelial cells.
Montalbano AM, Anzalone G, Albano GD, Sano CD, Gagliardo R, Bonanno A, Riccobono L, Nicolini G, Ingrassia E, Gjomarkaj M, Profita M.
Interesting experimental study that demonstrates how the association between Beclometasone and Formoterol can reduce the activation of oxidative mechanisms in bronchial epithelial cells subjected to exposure to cigarette smoke, protecting them from any oxidative damage.
FORMOTEROL AND EXTRA FINE BECLOMETASONE
Pulm Pharmacol Ther. 2013 Jun 14. pii: S1094-553900132-6.
Real life clinical study design supporting the effectiveness of extra-fine inhaledbeclomethasone / formoterol at the level of small airways of asthmatics.
Popov TA, Petrova D, Kralimarkova TZ, Ivanov Y, Popova T, Peneva M, Odzhakova T, Ilieva Y, Yakovliev P, Lazarova T, Georgiev O, Hodzhev V, Hodzheva E, Staevska MT, Dimitrov VD.
Study that demonstrates how the administration of Formoterol and Beclometasone in extra fine particles can determine a clear improvement of the symptoms present in asthma conditions, resulting in a better ability to penetrate into the bronchial epithelium.
BECLOMETHASONE FORMOTEROL IN COPD THERAPY
Int J Chron Obstruct Pulmon Dis. 2011; 6: 503-9. doi: 10.2147 / COPD.S23746. Epub 2011 Oct 4.
Effects of beclomethasone / formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, Olivieri D.
Interesting work that demonstrates how the maintenance therapy with Formoterol and Beclometasone extra fine, can determine a net improvement of dyspnea in patients with chronic obstructive pulmonary disease, thus determining a clear improvement of symptoms.
Method of use and dosage
Pressurized solution for inhalation of 100 mcg of Beclometasone dipropionate and 6 mcg of Formoterol fumarate dihydrate.
The therapeutic scheme varies considerably from patient to patient based on the characteristics of general health and the severity of his clinical picture.
The doctor should therefore set this therapy in a highly specific manner, taking care to define for each case the minimum dosage necessary to ensure a good control of the symptoms.
In any case, the maximum dosage should never exceed 4 daily inhalations.
Warnings FOSTER ® - Beclometasone + Formoterol
Therapy with FOSTER ® must necessarily be preceded and supervised by medical personnel, in order to evaluate the appropriateness of prescribing, efficacy and safety of the same.
It is also necessary to consider that therapy with FOSTER ® is not adequate for the treatment of acute asthma crisis.
Particular caution should obviously be reserved for patients suffering from cardiovascular pathologies, glaucoma, hyperthyroidism, pheochromocytoma, diabetes and prostatic hypertrophy, for which an aggravation of the clinical picture could be observed.
In order to limit the appearance of clinically relevant side effects, it would be advisable for the doctor to identify the minimum effective dose to ensure control of the symptoms and to inform the patient of all the potential side effects related to the therapy, so that the latter can recognize them promptly and alarm your doctor in time.
Although the systemic exposure to the two active ingredients is limited, it would be advisable for the doctor to also monitor the possible occurrence of systemic adverse reactions.
FOSTER ® is prohibited in and out of the race.
It is recommended to store the drug out of the reach of children.
PREGNANCY AND BREASTFEEDING
The aforementioned contraindications to the use of FOSTER ® also extend to pregnancy and the subsequent period of breastfeeding, given the absence of studies capable of fully characterizing the safety profile of the two active ingredients contained in the drug for the health of the fetus and infant.
The patient receiving FOSTER ® should avoid the concomitant intake of beta 2 agonist drugs and non-selective beta blockers, as well as diuretics, steroids and xanthine derivatives, potentially responsible for hypokalaemia.
Contraindications FOSTER ® - Beclometasone + Formoterol
The use of FOSTER ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients with severe heart disease, glaucoma, prostatic hypertrophy and urinary retention or intestinal obstruction syndrome:
Undesirable Effects - Side Effects
Therapy with FOSTER ®, especially when prolonged for a long time or carried out on particularly susceptible patients, could cause the onset of pharyngitis, headache, cough, hypokalaemia, muscle spasms, throat irritation, dysphonia and oral candidiasis.
Fortunately, the incidence of clinically more relevant side effects such as skin rash, hypersensitivity, urticaria, angioedema and cardiac manifestations is rarer.
FOSTER ® is a drug subject to mandatory medical prescription.
The information on FOSTER ® - Beclometasone + Formoterol published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.